These results demonstrate that nCRT enhances CEA and c-MET expression in tumor tissues, while EpCAM shows moderate differentiation, and EGFR remains predominantly expressed in normal epithelium, thus restricting its tumor-specific utility post-treatment. The gene discussed is CEACAM5; the disease is neoplasm.